8 completed, 4 unknown, 3 recruiting, 3 terminated. 21 Phase 2, 5 Phase 1, 4 Phase 3.
Follow Trigeminal Neuralgia: new trials by email Literature Review of Trigeminal Neuralgia trials Research Report on Trigeminal Neuralgia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia RP-008, Varenicline tartrate - Trigeminal Neuralgia | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 24 | 2026-09-10 | 2026-10-23 |
| Ultra-Early Gamma Knife Stereotactic Radiosurgery for TN GK SRS - Trigeminal Neuralgia (TN) | Phase 2 | Recruiting | University of Alberta | 80 | 2025-07-30 | 2026-10-23 |
| Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot Study myofascial pain, Orofacial bone pain, Orofacial Mucosal Pain - Cancer Pain, Orofacial Pain | Phase 2 | Recruiting | Shaukat Khanum Memorial Cancer Hospital & Research Centre | 40 | 2025-02-26 | 2026-11-05 |
| Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia SR750 tablet, Placebo - Trigeminal Neuralgia | Phase 2 | Completed | Shanghai SIMR Biotechnology Co., Ltd. | 138 | 2024-09-16 | 2026-04-24 |
| Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia Botulinum Toxin Type A for Injection,also known as "HengLi®" - Trigeminal Neuralgia | Phase 2 | Unknown | LKGS_277 | 240 | 2024-04-25 | 2024-05-13 |
| Nucleo CMP and Neurorubine Versus Carbamazepine for Classical Trigeminal Neuralgia Conventional Carbamazepine Therapy, Nucleo CMP and Neurorubine Combination - Trigeminal Neuralgia, Neuropathic Pain | Phase 2 | Completed | Karbala University | 38 | 2024-01-07 | 2025-12-26 |
| Paresthesia-free Peripheral Nerve Field Stimulation for Trigeminal Neuralgia (FreeST Trial) Paresthesia-free Peripheral Nerve Field Stimulation, Sham stimulation - Trigeminal Neuralgia, Facial Pain | Phase 1 / Phase 2 | Unknown | University Health Network, Toronto | 24 | 2022-10-28 | 2024-02-23 |
| An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. Basimglurant, Placebo - Trigeminal Neuralgia | Phase 2 / Phase 3 | Active not recruiting | Noema Pharma AG | 166 | 2022-01-11 | 2026-01-23 |
| Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy Lidocaine, Guanfacine - Trigeminal Neuralgia | Phase 2 | Completed | Vanderbilt University Medical Center | 37 | 2019-11-04 | 2025-03-30 |
| Efficacy and Tolerability of Erenumab in Patients With Trigeminal Neuralgia Erenumab, Placebos - Trigeminal Neuralgia | Phase 2 | Unknown | Danish Headache Center | 80 | 2019-10-28 | 2019-11-20 |
| Trial for Treatment Refractory Trigeminal Neuralgia Rimegepant, Placebo - Trigeminal Neuralgia | Phase 2 | Terminated | Pfizer | 65 | 2019-06-25 | 2024-06-10 |
| Glycerol Block of the Trigeminal Ganglion in Trigeminal Neuralgia Using a New Neuronavigation-based Surgical Technique Glycerol - Trigeminal Neuralgia, Headache Disorders | Phase 1 / Phase 2 | Terminated | Norwegian University of Science and Technology | 1 | 2016-05-01 | 2019-03-27 |
| Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues. Botulinum Toxin Type A - Trigeminal Neuralgia, Headache Disorders | Phase 1 / Phase 2 | Completed | Norwegian University of Science and Technology | 10 | 2016-05-01 | 2019-07-29 |
| Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia Carbon Dioxide Drug Delivery System (CDDS) - Trigeminal Neuralgia | Phase 2 | Completed | Capnia, Inc. | 30 | 2015-09-01 | 2017-11-17 |
| Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia Incobotulinumtoxina, Placebo Comparator - Trigeminal Neuralgia | Phase 2 | Terminated | Thomas Jefferson University | 6 | 2014-03-14 | 2023-06-28 |
| Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain ATNC05, Placebo - Atypical Facial Pain, Persistent Idiopathic Facial Pain | Phase 2 / Phase 3 | Withdrawn | Allodynic Therapeutics, Inc | 2014-03-01 | 2014-03-13 | |
| A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia CNV1014802, Placebo - Trigeminal Neuralgia | Phase 2 | Completed | Biogen | 67 | 2012-03-31 | 2019-01-10 |
| Clinical Trial of Hyperbaric Oxygen Treatment in Trigeminal Neuralgia Patients Hyperbaric oxygen, Mock hyperbaric chamber - Trigeminal Neuralgia, Pain | Phase 1 / Phase 2 | Unknown | Xijing Hospital | 30 | 2008-04-01 | 2009-03-20 |
| Efficacy and Safety Study of Lamotrigine to Treat Trigeminal Neuralgia Lamictal®, Tegretol® - Trigeminal Neuralgia | Phase 2 / Phase 3 | Completed | University of Malaya | 21 | 2007-09-01 | 2010-06-29 |
| Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception laboratory pain assessment, transcranial magnetic stimulation - Pain, Trigeminal Neuralgia | Phase 2 / Phase 3 | Withdrawn | Medical University of South Carolina | 2006-07-01 | 2012-04-30 |
Showing 20 of 21. Sign in to see all of them.
Facial Pain (4) · Pain (4) · Neuralgia (3) · Headache Disorders (2) · Cancer Pain (1) · Chronic Pain (1) · Complex Regional Pain Syndromes (1) · Facial Neuralgia (1) · Head and Neck Neoplasms (1) · Reflex Sympathetic Dystrophy (1) · Squamous Cell Carcinoma of Head and Neck (1)
Cranial Nerve Diseases (21) · Facial Nerve Diseases (21) · Mouth Diseases (21) · Nervous System Diseases (21) · Stomatognathic Diseases (21) · Trigeminal Nerve Diseases (21) · Facial Neuralgia (20) · Neurologic Manifestations (8) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Pain (4) · Neuromuscular Diseases (3) · Peripheral Nervous System Diseases (3) · Brain Diseases (2) · Central Nervous System Diseases (2)
Botulinum Toxins, Type A (2) · 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine (1) · Carbamazepine (1) · Dextromethorphan (1) · Glycerol (1) · Guanfacine (1) · Lamotrigine (1) · Lidocaine (1) · Saline Solution (1) · Sodium Chloride (1) · Transcranial Magnetic Stimulation (1) · Varenicline (1) · erenumab (1) · incobotulinumtoxinA (1) · rimegepant sulfate (1)
Norwegian University of Science and Technology (2) · Allodynic Therapeutics, Inc (1) · Biogen (1) · Capnia, Inc. (1) · Danish Headache Center (1) · Karbala University (1) · Kriya Therapeutics, Inc. (1) · LKGS_277 (1) · Medical University of South Carolina (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · Noema Pharma AG (1) · Pfizer (1) · Shanghai SIMR Biotechnology Co., Ltd. (1) · Shaukat Khanum Memorial Cancer Hospital & Research Centre (1) · Thomas Jefferson University (1)
United States (8) · Canada (3) · China (3) · Denmark (2) · Norway (2) · United Kingdom (2) · Germany (1) · Iraq (1) · Italy (1) · Malaysia (1) · Pakistan (1) · Poland (1) · Spain (1) · Turkey (Türkiye) (1)
Erling A Tronvik, PhD, MD (2) · Bifa Fan, MD (1) · Dr. Sameer Shaikh, MDSc. (1) · Jeffrey J. Borckardt, Ph.D. (1) · Lars Bendtsen, MD, Dr Med Sci (1) · Mojgan Hodaie, MD, MSc (1) · Stephen D Silberstein, MD (1) · Tigran Kesayan, MD (1)
PMID 21621166, PMID 28216232, PMID 30587219, PMID 31342515, PMID 40326696, PMID 41345955
2015 (1), K23NS050485 (1)